


World Journal of *Gastroenterology*

World J Gastroenterol 2023 February 7; 29(5): 766-907



EDITORIAL

- 766 Human leukocyte antigen antibodies and leukocyte antigen/killer-cell immunoglobulin-like receptor genes are important in transplant immunology in the liver
Muro M, Legaz I

OPINION REVIEW

- 773 Management of gastro-esophageal reflux disease: Practice-oriented answers to clinical questions
Frazzoni L, Fuccio L, Zagari RM

REVIEW

- 780 Transcriptome analysis creates a new era of precision medicine for managing recurrent hepatocellular carcinoma
Chiang CC, Yeh H, Lim SN, Lin WR
- 800 Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination
Nevola R, Criscuolo L, Beccia D, Delle Femine A, Ruocco R, Imbriani S, Alfano M, Villani A, Russo A, Perillo P, Marfella R, Adinolfi LE, Sasso FC, Marrone A, Rinaldi L

MINIREVIEWS

- 815 Outcomes of COVID-19 among patients with liver disease
Vujčić I
- 825 Bone loss in chronic liver diseases: Could healthy liver be a requirement for good bone health?
Jadzic J, Djonic D
- 834 Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features
Ippolito D, Maino C, Vernuccio F, Cannella R, Inchingolo R, Dezio M, Faletti R, Bonaffini PA, Gatti M, Sironi S

ORIGINAL ARTICLE

Basic Study

- 851 *Saccharomyces cerevisiae* prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats
Valibouze C, Specia S, Dubuquoy C, Mourey F, M'Ba L, Schneider L, Titecat M, Foligné B, Genin M, Neut C, Zerbib P, Desreumaux P
- 867 Impact of endothelial nitric oxide synthase activation on accelerated liver regeneration in a rat ALPPS model
Masuo H, Shimizu A, Motoyama H, Kubota K, Notake T, Yoshizawa T, Hosoda K, Yasukawa K, Kobayashi A, Soejima Y

Retrospective Study

- 879** Convolutional neural network-based segmentation network applied to image recognition of angiodysplasias lesion under capsule endoscopy

Chu Y, Huang F, Gao M, Zou DW, Zhong J, Wu W, Wang Q, Shen XN, Gong TT, Li YY, Wang LF

Clinical Trials Study

- 890** Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma

Simasingha N, Tanasoontrarat W, Claimon T, Sethasine S

LETTER TO THE EDITOR

- 904** Timing of biliary decompression for acute cholangitis

Yang J, Liu Y, Liu S

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Jian-Gao Fan, PhD, Professor and Director, Center for Fatty Liver Disease, Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Key Laboratory of Children's Digestion and Nutrition, Shanghai 200092, China.
fattyLiver2004@126.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

February 7, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Outcomes of COVID-19 among patients with liver disease

Isidora Vujčić

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Ariyachet C, Thailand; El-Gendy HA, Egypt; Sitkin S, Russia

Received: September 17, 2022

Peer-review started: September 17, 2022

First decision: November 15, 2022

Revised: December 25, 2022

Accepted: January 20, 2023

Article in press: January 20, 2023

Published online: February 7, 2023



Isidora Vujčić, Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade 11000, Belgrade, Serbia

Corresponding author: Isidora Vujčić, MD, PhD, Associate Professor, Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Visegradska 26a, Belgrade 11000, Belgrade, Serbia. isidora.vujcic@med.bg.ac.rs

Abstract

Coronavirus disease 2019 (COVID-19) is primarily a respiratory disease with multi-organ involvement, including impaired liver function. It has been noticed that a significant proportion of COVID-19 patients have liver dysfunction, especially those with a more severe disease course. The coronavirus causes direct damage to the liver using the angiotensin-converting enzyme 2, a cell-surface receptor for cellular entry, that is expressed in the liver. According to previous research, liver enzyme abnormalities were observed in a considerable proportion of COVID-19 patients, and elevated liver transaminases were found in about 20% of these patients, alkaline phosphatase in 6.1%, and gamma-glutamyl transferase in 21.1%. COVID-19 might trigger a deterioration of liver function in patients with pre-existing chronic liver diseases (CLDs) and also in those without previous liver disorders. The majority of COVID-19 patients who develop liver injury are men, the elderly, and those with a higher body mass index. Compared to the general population, COVID-19 is associated with significant morbidity and mortality in patients with liver disease (cirrhosis and liver transplantation recipients). However, some studies indicate that CLDs have a lesser role in determining patient progression towards higher disease severity.

Key Words: Liver disease; COVID-19; Mortality; Prognosis; Liver function

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Drastic lifestyle changes during the coronavirus disease 2019 (COVID-19) pandemic have led to an increase in the incidence of liver disease. Liver damage in COVID-19 infection occurs during disease progression in patients with or without previous liver disorders and represents a risk factor for developing severe illness and death. The prognosis of COVID-19 infection depends predominantly on the patients' characteristics, present comorbidities, severity of clinical symptoms, laboratory parameters, and imaging features. It is important to examine prognostic factors in COVID-19 disease patients with liver disease because it may improve the outcome.

Citation: Vujčić I. Outcomes of COVID-19 among patients with liver disease. *World J Gastroenterol* 2023; 29(5): 815-824

URL: <https://www.wjgnet.com/1007-9327/full/v29/i5/815.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v29.i5.815>

INTRODUCTION

The coronavirus disease (COVID-19) originated in late 2019 in China and spread with alarming rapidity across the globe[1]. The illness is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and during the pandemic, more than 600 million cases and more than 6 million deaths were reported worldwide[2]. COVID-19 clinical manifestations vary, and the disease's wide clinical spectrum ranges from mild, self-limiting pulmonary tract infection to progressive severe pneumonia with high mortality rates[3]. Drastic lifestyle changes during the COVID-19 pandemic have led to an increase in the incidence of nonalcoholic fatty liver disease (NAFLD), decompensated cirrhosis, acute alcoholic hepatitis, viral hepatitis, and mortality from liver diseases[4]. Liver dysfunction in COVID-19 patients is a risk factor for severe illness and death[5], and significantly higher morbidity and mortality rates were observed among patients with liver disease and COVID-19, compared to the general population[6]. About 2%-11% of COVID-19 patients had already been diagnosed with chronic liver disease (CLD)[7]. However, liver dysfunction includes a variety of etiologies and heterogeneous groups of patients[8]. In addition, COVID-19 can induce liver injury, especially in those patients with severe forms of the disease[7,9].

GLOBAL BURDEN OF LIVER DISEASES

Globally, two million deaths are attributed to liver diseases, including 1 million due to cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma (HCC)[10]. Over the past two decades, the prevalence of CLD has been increasing[11]. CLD includes NAFLD, alcohol-related liver disease (ALD), and chronic viral hepatitis B and C[12], and it can progress to fibrosis, cirrhosis, and HCC[13]. NAFLD, or the recently defined metabolic-associated fatty liver disease (MAFLD), are the most common CLDs, which affect about a quarter of the world's adult population[14]. The global prevalence of MAFLD/NAFLD has been rapidly increasing in tandem with the rise in diabetes and obesity prevalence, both of which have been associated with increased mortality in COVID-19[15,16]. Hepatitis B and C are still a major cause of liver disease burden globally, especially in low-income countries in Asia and sub-Saharan Africa, despite the availability of effective preventive measures and treatment[10,17].

LIVER INJURY IN CORONAVIRUS INFECTED PATIENTS

Although coronavirus can cause the worst damage to the lungs, it can also influence the digestive, cardiac, and endocrine systems[18]. Multifactorial causes of liver damage during COVID-19 infection include direct virus cytopathogenic effect, abnormal immune response associated with the cytokine storm, vascular changes due to coagulopathy, hepatic ischemia/hypoxia reperfusion injury, and drug-induced liver injury[19,20]. The coronavirus causes direct liver injury using the angiotensin converting enzyme 2 receptor for cellular entry, which is expressed mainly in the cholangiocytes and less frequently in the hepatocytes[21]. Certain hepatotoxic medications, such as antibiotics (macrolides, quinolones), antivirals (ribavirin), steroids, and other drugs used to treat patients with COVID-19, are connected with drug-induced liver injury and were found in 10.9% of COVID-19 patients[22-24]. However, in COVID-19 patients, liver damage is primarily secondary to ischemic, hypercoagulable, and hyperinflammatory states, which are independent predictors of death rather than liver injury per se [21]. A cytokine storm and a massive acute-phase response are defined by the acute overproduction and uncontrolled release of the proinflammatory cytokines, tumor necrosis factor (TNF), interleukin 1 (IL-1),

and IL-6 paralleled by excessive secretion of C-reactive protein (CRP) and ferritin[25]. Coagulation dysfunction indicates a poor outcome in critically ill COVID-19 patients with hepatic injury, including a significant role of neutrophils and monocytes in amplifying blood clotting[20]. Hepatic apoptosis and elevated liver enzymes are caused by ischemia and reperfusion injury[20].

PROGNOSTIC FACTORS IN COVID-19 PATIENTS WITH LIVER DISEASE

Advanced age and being male are well-established risk factors for severe COVID-19 outcomes[26]. Various medical underlying conditions, such as cardiovascular disease, lung disease, cancer, diabetes, and obesity have also been associated with increased risk[27-29]. However, the prognostic factors in COVID-19 patients with previous liver diseases are not well-defined[9]. In a multicenter cohort study conducted in the United States, comorbidities such as diabetes, hypertension, chronic obstructive pulmonary disease, current smoking and increasing age in patients with ALD, liver cirrhosis decompensation, and HCC predicted a higher mortality when infected with COVID-19[11]. In another study from the United States conducted among CLD patients, it was reported that older age and pre-existing comorbidities were associated with severe COVID-19[30]. Shen *et al*[31] found that COVID-19 patients with liver injury had a significantly poorer prognosis than patients without liver dysfunction, and that male sex and elevated CRP were independent prognostic factors in these patients[31]. Preliminary results of a systematic review and meta-analysis involving 88 studies and 6653207 cases of COVID-19 in Europe showed that liver disease was associated with hospital admission and mortality, after adjustment for age and sex[32]. Liver dysfunction during COVID-19 has been associated with increased disease severity, prolonged hospital stays, ventilatory support and mortality[33].

Liver injury, laboratory findings, and prognosis

The prognosis of the COVID-19 infection depends primarily on the patients' characteristics, present comorbidities, severity of clinical symptoms, laboratory parameters, and imaging features[34] (Figure 1). Liver injury occurs in patients with or without pre-existing liver disorders[24]. The incidence of liver injury manifesting as abnormal levels of liver enzymes ranges from 14.8% to 53.0%[18]. The degree of liver injury is generally mild, and those with digestive symptoms were more likely to present hepatocellular injury[3,35,36]. COVID-19 patients who develop liver injury are more likely to be men, older, and have a higher body mass index (BMI)[37]. Liver enzyme abnormalities are frequent in patients with COVID-19 infection, and they are associated with disease severity[18,38]. The most frequently reported mild to moderate elevations were in aspartate aminotransferase (ALT), alanine aminotransferase (AST), and total bilirubin (tBIL) levels[35], but abnormal gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and albumin levels have been found in patients with COVID-19 as well[18,22,39]. Liver damage in COVID-19 is usually temporary, and therefore, the enzyme levels of most patients usually return to normal after recovery[18,40]. The systematic review and meta-analysis that included 36 studies and 20724 patients found a 46.9% prevalence of at least one abnormal liver function test, and elevated levels of ALT, AST, and tBIL were independent predictors of COVID-19 severity and in-hospital mortality[41]. A meta-analysis of observational studies revealed that acute liver injury and elevated liver enzymes in COVID-19 patients were significantly associated with disease severity[42]. A study conducted in Hong Kong reported that, ALT/AST elevation at two times the upper normal limit and acute liver injury in patients with COVID-19, were independently associated with poor prognosis, after controlling for diabetes mellitus, hypertension, and albumin level[43]. A systematic review that included 30 articles observed a significantly higher mortality in patients with impaired liver function than in patients with normal function[36]. Wagner *et al*[44] reported that hypoalbuminemia and abnormalities in liver function tests may be prognostic factors for higher COVID-19 severity. Although, there remains controversy in the scientific literature over whether or not liver enzyme abnormalities are associated with worse clinical outcomes, their alteration probably reflects the systemic involvement of the virus and the potential appearance of severe liver complications[45]. However, patients with severe COVID-19 may show a higher risk of post-COVID cholangiopathy, and liver tests in these patients continue to show abnormal results[46].

COVID-19 IN PATIENTS WITH PRE-EXISTING LIVER DISEASE

A number of studies have investigated the impact of CLD on the outcome of COVID-19[8]. COVID-19 patients with CLD account for less than 1% of the reported cases[47]. CLD includes different etiologies and can manifest from mild asymptomatic disease to severe decompensated cirrhosis, so it could be challenging to generalize results from different studies and countries[11,17]. In China, the main cirrhosis etiology was chronic hepatitis B virus (HBV)[48]. Patients with viral hepatitis, ALD, NFALD, liver cirrhosis, and HCC had a higher risk of developing severe COVID-19 and up to a 10-fold higher mortality rate compared to those without any reported comorbidity[49]. Data collected from 13 Asian




Figure 1 Prognostic factors in COVID-19 patients with liver disease. BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease; MAFLD: Metabolic-associated fatty liver disease.

countries identified that COVID-19 infection induced significant liver damage in CLD patients, and these patients had a higher risk of getting acute liver injury, hepatic decompensation, or acute-on-chronic liver failure (ACLF)[50]. A Danish prospective, population-based cohort study reported that patients with CLD, particularly those with cirrhosis, were at a major risk of severe COVID-19 outcomes and higher mortality[51]. A Swedish nationwide matched cohort study showed that patients with CLD had a higher risk of hospitalization for COVID-19 compared to the general population[52]. However, there was no evidence that these patients were at a higher risk of developing a severe COVID-19 disease course[52]. A study conducted in China reported that COVID-19 patients with CLD showed a prolonged length of stay, slight liver injuries, and higher mortality rates compared to COVID-19 patients without CLD, and that the neutrophil-to-lymphocyte ratio was an indicator of adverse clinical outcomes in this population[53]. A meta-analysis that included fifty studies revealed that pre-existing liver diseases or acute liver injury associated with severe COVID-19 infection were key factors in the prediction of mortality[54]. According to a study conducted in Massachusetts, United States, CLD in patients with COVID-19 was independently associated with higher rates of intensive care unit (ICU) admission, and a need for mechanical ventilation after controlling for comorbidities[12]. Krishnan *et al* [30] found that CLD patients with elevated AST and tBIL levels had a significantly higher risk for a more severe COVID-19 disease course and also reported that ALD was the most important factor associated with the need for mechanical ventilation. A systematic review including 40 studies, mainly from China, reported that CLD was significantly associated with COVID-19 severity and mortality[55]. The risk of getting more severe COVID-19 was 2.44 times higher among patients with CLD compared to those without CLD, and the presence of NAFLD was the most strongly associated with higher COVID-19 severity, followed by MAFLD and cirrhosis. In addition, COVID-19 patients with viral hepatitis were not at higher risk of getting a severe form of COVID-19[55]. After COVID-19 infection, approximately 20% of CLD patients develop progressive cholestasis, particularly patients with NAFLD/non-alcoholic steatohepatitis and metabolic risk factors[56].

COVID-19 and viral hepatitis

There is still insufficient evidence for an association between previous hepatitis B and C infection and COVID-19 outcome, and several studies indicated that these patients were not at increased risk for severe COVID-19[57-59]. Most studies that have examined the influence of HBV on COVID-19 prognosis have been conducted in China due to the high prevalence of HBV in the country[60]. Yu *et al* [61] reported higher in-hospital mortality, more severe disease, and liver function abnormalities in COVID-19 patients infected with HBV compared to COVID-19 patients without HBV. However, the presence of COVID-19 infection or treatment with tocilizumab or corticosteroids could reactivate hepatitis B infection[49,62]. A study conducted in the United States reported that chronic hepatitis C in COVID-19 patients was associated with in-hospital mortality regardless of baseline comorbidities, admission values of laboratory tests, or liver damage induced by COVID-19[63]. The Korean nationwide population-based cohort study reported that after adjusting for age, sex, cirrhosis, and comorbidities, HBV infection itself appears not to influence the prognosis of COVID-19 patients[64].

COVID-19 and NAFLD

The prevalence of NAFLD, or the recently renamed MAFLD, in COVID-19 patients is 31%, which is higher than the prevalence in the general population[65]. Patients with NAFLD had a higher risk of COVID-19 progression, a higher likelihood of liver dysfunction, and a longer viral shedding time than the patients without NAFLD[66]. Mahamid *et al*[16] found an independent association between the COVID-19 severity and NAFLD irrespective of the metabolic syndrome, indicating that NAFLD had a significant impact even in the absence of obesity and/or metabolic syndrome. A systematic review and meta-analysis showed that the proportion of patients with MAFLD and NAFLD ranged from 28% to 50% and from 6% to 38%, respectively, and found that the presence of MAFLD and NAFLD was associated with worse clinical outcomes for COVID-19[67]. Although several studies also showed significant associations between MAFLD and NAFLD and severe COVID-19 outcomes[13,68], there is still no strong evidence that the presence of MAFLD affects its prognosis[65].

COVID-19 and ALD

The COVID-19 pandemic probably had the biggest effect on patients with ALD due to substantially increased alcohol consumption provoked by adverse economic effects, disruptions in work and education, and social isolation[69]. Patients with alcohol use disorders are more likely to develop acute respiratory distress syndrome and have additional comorbidities such as metabolic syndrome, chronic kidney disease, and smoking, all of which are independent predictors of COVID-19 severity[69]. Several studies have identified that ALD is independently associated with COVID-19 mortality after adjustment for important cofactors such as liver disease severity[11,70].

COVID-19 and cirrhosis

COVID-19 patients with cirrhosis are at a greater risk of adverse outcomes than the background population[26,71,72]. Cirrhotic patients have significantly higher all-cause mortality in COVID-19 infection than non-cirrhotic patients, and mortality is probably higher in those with more advanced cirrhosis[8]. A significantly higher COVID-19 related morbidity and mortality had been observed in patients with decompensated cirrhosis compared to those with compensated cirrhosis[6]. Studies conducted in the United States and Europe reported that patients with CLD who had acquired COVID-19 had high rates of hospitalization and mortality[71,73,74]. Marjot *et al*[70] reported that patients with cirrhosis had a higher risk of dying from COVID-19 and that mortality was especially high among patients with more advanced cirrhosis and those with ALD. Hashemi *et al*[12] demonstrated that the presence of cirrhosis was independently associated with COVID-19-related mortality. Similar results were obtained from the United States study, reporting that the presence of decompensated cirrhosis was an independent predictor of mortality in COVID-19 patients[30]. Jeon *et al*[75] reported that the COVID-19 infection in patients with cirrhosis was more likely to cause severe complications in comparison with the cirrhotic patients not infected with COVID-19. Satapathy *et al*[76] found that the development of ACLF was the most important predictor of higher in-hospital mortality in COVID-19 patients with cirrhosis. However, it is still unknown whether the presence of liver disease influences the natural history of COVID-19 infection in cirrhotic patients[21].

COVID-19 and hepatocellular carcinoma

The presence of HCC in patients with CLD and COVID-19 infection was associated with a poor prognosis, including a higher risk of all-cause and COVID-19-related mortality[11]. Most HCC patients have concomitant cirrhosis, and that could potentially increase their risk for severe COVID-19[77]. An international, multicenter, retrospective, cross-sectional study, including two hundred fifty patients from 38 centers, reported that 18.4% of patients with HCC died within the first 30 d from the onset of COVID-19 symptoms, and that the mortality rate in that period was 20.25% in patients with HCC history and 12.96% in those with de novo HCC[78]. COVID-19 in HCC patients tends to be more severe and leads to exacerbation of the liver disease[79]. HCC patients infected with COVID-19 are at a higher risk of complications, ICU admission, and death than the patients without cancer[80].

COVID-19 and autoimmune liver disease

Autoimmune liver disease (AILD) includes primary sclerosing cholangitis, primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), and overlapping syndromes referring to the coexistence of two autoimmune diseases[81]. COVID-19 outcomes in patients with AILD were investigated in international registry studies and retrospective case studies[82]. Combined data from three multinational registries showed that despite the use of immunosuppressive treatment, AIH patients did not seem to have a higher risk of lethal outcomes with COVID-19 compared to patients without liver disease and those with other forms of liver disease[83]. A retrospective study from 34 centers in Europe and the Americas indicated that patients with AIH did not have an increased risk for poor prognosis with COVID-19 than other causes of CLD and that cirrhosis was the most important predictor for high COVID-19 severity in this group of patients[84]. Zecher *et al*[85] indicated that patients with AILD were not at elevated risk for COVID-19. A Spanish nationwide study reported that cumulative incidences of hospitalization and COVID-19 related mortality were greater in patients with PBC than in the general Spanish population,

although the results were not adjusted for other comorbidities[86].

Severity and mortality of COVID-19 among CLD patients

Although the presence of COVID-19 infection in CLD patients is associated with a poor prognosis, including severity and mortality, these results should be interpreted with caution and need to be evaluated in large future studies. Such findings could be explained by overlapping risk factors, therapeutic effort limitations, different etiologies, and the disease spectrum of CLD, which ranges from mild asymptomatic disease to severe decompensated cirrhosis. Cirrhosis severity and older age are the most important predictors of mortality[21]. A French national retrospective cohort study found no increased COVID-19 severity in patients with CLD, alcohol use disorders, cirrhosis, or primary liver cancer, indicating that the COVID-19 outcome in these patients may be more associated with therapeutic effort such as mechanical ventilation and less with liver disease progression or ethanol toxicity[87]. This group of patients was at an elevated risk for mortality from COVID-19 within 30 d after admission but was less likely to need mechanical ventilation[87] in comparison with patients with mild liver diseases, compensated cirrhosis, chronic viral hepatitis, non-viral, non-alcoholic causes of CLD, acquired immunodeficiency syndrome, and liver transplantation, who were not at a higher risk of dying from COVID-19 but were more likely to receive mechanical ventilation[87]. As mentioned earlier, the Swedish nationwide cohort study also did not find an increased risk of getting severe COVID-19 in CLD patients, although they had an increased risk of hospitalization than the background population [52]. The pooled analysis of six studies found that CLD was not related to an elevated risk of a more severe COVID-19 disease course or mortality[88]. Similar results were reported from a nationwide Korean cohort study indicating that LC was not an independent predictor of severe complications, including mortality, in COVID-19 patients and depended on age, hypertension, cancer, chronic obstructive pulmonary disease, and a higher Charlson comorbidity index[75]. After adjustment for age, sex, BMI, cardiac disease, hypertension, diabetes, and respiratory disorders, CLD, and NAFLD were independently associated with ICU admission and the need for mechanical ventilation, but not death [12].

CONCLUSION

Due to the era of the COVID-19 pandemic and the large number of patients with liver disease, it is very important to study the impact of liver damage on the prognosis of patients with COVID-19 and the predictors that may affect the outcome. Identifying predictors of mortality could allow for risk stratification of patients and help improve healthcare delivery[11]. Therefore, it is necessary to improve the understanding of host genetics, behavior, and pre-existing comorbidities and adequately follow-up liver disease patients[17]. Patients with CLD, especially those with cirrhosis or advanced liver damage, should be prioritized for COVID-19 vaccination[89].

FOOTNOTES

Author contributions: Isidora Vujcic wrote the manuscript and performed the literature search.

Conflict-of-interest statement: The author states there is no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Serbia

ORCID number: Isidora Vujčić [0000-0003-3442-7400](https://orcid.org/0000-0003-3442-7400).

S-Editor: Chen YL

L-Editor: Filipodia

P-Editor: Chen YL

REFERENCES

- 1 European Centre for Disease Prevention and Control. COVID-19. [cited 3 December 2022]. Available from:

- <https://www.ecdc.europa.eu/en>
- 2 **World Health Organization.** Coronavirus disease (COVID-19). [cited 3 December 2022]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
 - 3 **Garrido M,** Pereira Guedes T, Alves Silva J, Falcão D, Novo I, Archer S, Rocha M, Maia L, Sarmiento-Castro R, Pedroto I. Impact of Liver Test Abnormalities and Chronic Liver Disease on the Clinical Outcomes of Patients Hospitalized with COVID-19. *GE Port J Gastroenterol* 2021; **158**: 1-12 [PMID: [34192127](#) DOI: [10.1159/000513593](#)]
 - 4 **Mikolasevic I,** Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? *World J Gastroenterol* 2021; **27**: 6039-6052 [PMID: [34629818](#) DOI: [10.3748/wjg.v27.i36.6039](#)]
 - 5 **Jaiswal V,** Naz S, Ishak A, Batra N, Quinonez J, Mukherjee D, Pokhrel NB. A rare case of pediatric pancreatic pseudocyst. *Clin Case Rep* 2022; **10**: e05879 [PMID: [35600019](#) DOI: [10.1002/ccr3.5879](#)]
 - 6 **Choudhary NS,** Dhampalwar S, Saraf N, Soin AS. Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation. *J Clin Exp Hepatol* 2021; **11**: 713-719 [PMID: [33994708](#) DOI: [10.1016/j.jceh.2021.05.003](#)]
 - 7 **Jothamani D,** Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. *J Hepatol* 2020; **73**: 1231-1240 [PMID: [32553666](#) DOI: [10.1016/j.jhep.2020.06.006](#)]
 - 8 **Middleton P,** Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. *BMJ Open Gastroenterol* 2021; **8** [PMID: [34675033](#) DOI: [10.1136/bmjgast-2021-000739](#)]
 - 9 **Bahardoust M,** Heiat M, Khodabandeh M, Karbasi A, Bagheri-Hosseinabadi Z, Ataee MH, Seidalian N, Babazadeh A, Agah S, Abyazi MA. Predictors for the severe coronavirus disease 2019 (COVID-19) infection in patients with underlying liver disease: a retrospective analytical study in Iran. *Sci Rep* 2021; **11**: 3066 [PMID: [33542426](#) DOI: [10.1038/s41598-021-82721-3](#)]
 - 10 **Asrani SK,** Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019; **70**: 151-171 [DOI: [10.1016/j.jhep.2018.09.014](#)]
 - 11 **Kim D,** Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. *Clin Gastroenterol Hepatol* 2021; **19**: 1469-1479.e19 [PMID: [32950749](#) DOI: [10.1016/j.cgh.2020.09.027](#)]
 - 12 **Hashemi N,** Viveiros K, Redd WD, Zhou JC, McCarty TR, Bazarbashi AN, Hathorn KE, Wong D, Njie C, Shen L, Chan WW. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience. *Liver Int* 2020; **40**: 2515-2521 [PMID: [32585065](#) DOI: [10.1111/liv.14583](#)]
 - 13 **Hayat U,** Ashfaq MZ, Johnson L, Ford R, Wuthnow C, Kadado K, El Jurdi K, Okut H, Kilgore WR, Assi M, Siddiqui AA. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis. *Kans J Med* 2022; **15**: 241-246 [PMID: [35899064](#) DOI: [10.17161/kjm.vol15.16522](#)]
 - 14 **Eslam M,** Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: [32044314](#) DOI: [10.1053/j.gastro.2019.11.312](#)]
 - 15 **Testino G.** Covid-19 infection, liver injury and prognosis: a suggestion. *Eur J Gastroenterol Hepatol* 2021; **33**: 451-452 [PMID: [32558696](#) DOI: [10.1097/MEG.0000000000001809](#)]
 - 16 **Mahamid M,** Nseir W, Khoury T, Mahamid B, Nubania A, Sub-Laban K, Schifter J, Mari A, Sbeit W, Goldin E. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. *Eur J Gastroenterol Hepatol* 2021; **33**: 1578-1581 [PMID: [32868652](#) DOI: [10.1097/MEG.0000000000001902](#)]
 - 17 **Fierro NA.** COVID-19 and the liver: What do we know after six months of the pandemic? *Ann Hepatol* 2020; **19**: 590-591 [PMID: [32956871](#) DOI: [10.1016/j.aohep.2020.09.001](#)]
 - 18 **Wang X,** Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. *Front Med (Lausanne)* 2021; **8**: 651658 [PMID: [34646834](#) DOI: [10.3389/fmed.2021.651658](#)]
 - 19 **Ozkurt Z,** Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. *World J Clin Cases* 2022; **10**: 1140-1163 [PMID: [35211548](#) DOI: [10.12998/wjcc.v10.i4.1140](#)]
 - 20 **Elghannam MT,** Hassanien MH, Ameen YA, ELattar GM, ELRay AA, Turkey EA, ELTalkawy MD. COVID-19 and liver diseases. *Egypt Liver J* 2022; **12**: 43 [PMID: [35880136](#) DOI: [10.1186/s43066-022-00202-2](#)]
 - 21 **Russo FP,** Burra P, Zanetto A. COVID-19 and liver disease: where are we now? *Nat Rev Gastroenterol Hepatol* 2022; **19**: 277-278 [PMID: [35301465](#) DOI: [10.1038/s41575-022-00607-9](#)]
 - 22 **Taneva G,** Dimitrov D, Velikova T. Liver dysfunction as a cytokine storm manifestation and prognostic factor for severe COVID-19. *World J Hepatol* 2021; **13**: 2005-2012 [PMID: [35070004](#) DOI: [10.4254/wjh.v13.i12.2005](#)]
 - 23 **Wu J,** Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. *World J Gastroenterol* 2020; **26**: 2286-2293 [PMID: [32476793](#) DOI: [10.3748/wjg.v26.i19.2286](#)]
 - 24 **Kanda T,** Sasaki-Tanaka R, Ishii T, Abe H, Ogawa M, Enomoto H. Acute Liver Failure and Acute-on-Chronic Liver Failure in COVID-19 Era. *J Clin Med* 2022; **11** [PMID: [35888013](#) DOI: [10.3390/jcm11144249](#)]
 - 25 **Dufour JF,** Marjot T, Becchetti C, Tilg H. COVID-19 and liver disease. *Gut* 2022; **71**: 2350-2362 [PMID: [35701093](#) DOI: [10.1136/gutjnl-2021-326792](#)]
 - 26 **Williamson EJ,** Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**: 430-436 [PMID: [32640463](#) DOI: [10.1038/s41586-020-2521-4](#)]
 - 27 **Deng G,** Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. *Crit Care* 2020; **24**: 179 [PMID: [32345311](#) DOI: [10.1186/s13054-020-02902-w](#)]
 - 28 **Figliozzi S,** Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, Stamatelopoulou K, Dimopoulos MA, Caforio ALP,

- Georgiopoulos G. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest* 2020; **50**: e13362 [PMID: 32726868 DOI: 10.1111/eci.13362]
- 29 **Yang J**, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: An updated systematic review and meta-analysis. *J Med Virol* 2021; **93**: 2662-2674 [PMID: 33200825 DOI: 10.1002/jmv.26677]
- 30 **Krishnan A**, Prichett L, Liu Y, Ting PS, Alqahtani SA, Kim AK, Ma M, Hamilton JP, Woreta TA, Chen PH. Risk of Severe Illness and Risk Factors of Outcomes of COVID-19 in Hospitalized Patients with Chronic Liver Disease in a Major U. S. Hospital Network. *Can J Gastroenterol Hepatol* 2022; **2022**: 8407990 [PMID: 36387036 DOI: 10.1155/2022/8407990]
- 31 **Shen JX**, Zhuang ZH, Zhang QX, Huang JF, Chen GP, Fang YY, Cheng AG. Risk Factors and Prognosis in Patients with COVID-19 and Liver Injury: A Retrospective Analysis. *J Multidiscip Healthc* 2021; **14**: 629-637 [PMID: 33731999 DOI: 10.2147/JMDH.S293378]
- 32 **Vardavas CI**, Mathioudakis AG, Nikitara K, Stamatelopoulou K, Georgiopoulos G, Phalkey R, Leonardi-Bee J, Fernandez E, Carnicer-Pont D, Vestbo J, Semenza JC, Deogan C, Suk JE, Kramarz P, Lamb F, Penttinen P. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. *Eur Respir Rev* 2022; **31** [PMID: 36323422 DOI: 10.1183/16000617.0098-2022]
- 33 **Ortega-Quiroz RJ**. COVID-19 and Liver Disease: A panorama that is being clarified. *Rev Colomb Gastroenterol* 2022; **37**: 131-135 [DOI: 10.22516/]
- 34 **Besteiro B**, Coutinho D, Gomes F, Almeida M, Almeida J. Review of the Prognosis Factors of COVID-19 Infection. *Adv Infect Dis* 2021; **11**: 196-215 [DOI: 10.4236/aid.2021.112019]
- 35 **Kariyawasam JC**, Jayarajah U, Abeyesuriya V, Riza R, Seneviratne SL. Involvement of the Liver in COVID-19: A Systematic Review. *Am J Trop Med Hyg* 2022; **106**: 1026-1041 [PMID: 35203056 DOI: 10.4269/ajtmh.21-1240]
- 36 **Almeida-Costa T**, Cunha-Lima MA, Kniess I, Marques-Vieira L, Delmondes-Freitas LD. Changes in liver function tests caused by COVID-19 and impact on patient outcome: a systematic review. *Rev Colomb Gastroenterol* 2021; **36**: 302-312 [DOI: 10.22516/25007440.713]
- 37 **Cichoż-Lach H**, Michalak A. Liver injury in the era of COVID-19. *World J Gastroenterol* 2021; **27**: 377-390 [PMID: 33584070 DOI: 10.3748/wjg.v27.i5.377]
- 38 **Wu Y**, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. *Hepatol Int* 2020; **14**: 621-637 [PMID: 32710250 DOI: 10.1007/s12072-020-10074-6]
- 39 **Tokarczyk U**, Kaliszewski K, Kopszak A, Nowak Ł, Sutkowska-Stępień K, Sroczynski M, Sępek M, Dudek A, Diakowska D, Trocha M, Gajecski D, Gawryś J, Matys T, Maciejczek J, Kozub V, Szalast R, Madziarski M, Zubkiewicz-Zarębska A, Letachowicz K, Kiliś-Pstrusińska K, Matera-Witkiewicz A, Pomorski M, Protasiewicz M, Sokołowski J, Adamik B, Kujawa K, Doroszko A, Madziarska K, Jankowska EA. Liver Function Tests in COVID-19: Assessment of the Actual Prognostic Value. *J Clin Med* 2022; **11** [PMID: 35956107 DOI: 10.3390/jcm11154490]
- 40 **Liao X**, Li D, Ma Z, Zhang L, Zheng B, Li Z, Li G, Liu L, Zhang Z. 12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study. *Front Cell Infect Microbiol* 2022; **12**: 864933 [PMID: 35493732 DOI: 10.3389/fcimb.2022.864933]
- 41 **Del Zompo F**, De Siena M, Ianaro G, Gasbarrini A, Pompili M, Ponziani FR. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. *Eur Rev Med Pharmacol Sci* 2020; **24**: 13072-13088 [PMID: 33378061 DOI: 10.26355/eurev_202012_24215]
- 42 **Sharma A**, Jaiswal P, Kerakhan Y, Saravanan L, Murtaza Z, Zergham A, Honganur NS, Akbar A, Deol A, Francis B, Patel S, Mehta D, Jaiswal R, Singh J, Patel U, Malik P. Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis. *Ann Hepatol* 2021; **21**: 100273 [PMID: 33075578 DOI: 10.1016/j.aohp.2020.10.001]
- 43 **Yip TC**, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. *Gut* 2021; **70**: 733-742 [PMID: 32641471 DOI: 10.1136/gutjnl-2020-321726]
- 44 **Wagner J**, Garcia-Rodriguez V, Yu A, Dutra B, Larson S, Cash B, DuPont A, Farooq A. Elevated transaminases and hypoalbuminemia in Covid-19 are prognostic factors for disease severity. *Sci Rep* 2021; **11**: 10308 [PMID: 33986318 DOI: 10.1038/s41598-021-89340-y]
- 45 **Quintero-Marzola ID**, Fontalvo-Mendoza MF, Cárdenas-Gómez JC, Quintana-Pájaro LJ, Ramos-Villegas Y, Manzur-Jattin F, Yepes IJ, Sibaja-Pérez AE. Liver and SARS-CoV-2: Literature key aspects. *Rev Colomb Gastroenterol* 2021; **36**: 485-493 [DOI: 10.22516/25007440.619]
- 46 **Rojas M**, Rodríguez Y, Zapata E, Hernández JC, Anaya JM. Cholangiopathy as part of post-COVID syndrome. *J Transl Autoimmun* 2021; **4**: 100116 [PMID: 34485887 DOI: 10.1016/j.jtauto.2021.100116]
- 47 **Elghannam MT**, Hassanien MH, Abdelrahman Y, Alattar GM, Turkey EA, EL Ray AA, EL Talkawy MD. (2021) COVID-19 and Chronic Viral Liver Diseases. *J Biosci Med* 2021; **9**: 138-146 [DOI: 10.4236/jbm.2021.99012]
- 48 **Qi X**, Liu Y, Wang J, Fallowfield JA, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rokey DC; COVID-Cirrhosis-CHESS Group. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. *Gut* 2021; **70**: 433-436 [PMID: 32434831 DOI: 10.1136/gutjnl-2020-321666]
- 49 **Taye BW**, Valery PC, Clark PJ. Protecting persons at-risk of viral hepatitis and alcohol-related liver disease during the pandemic and beyond: mitigating the impact of coronavirus disease 2019 on liver health. *J Glob Health Rep* 2021; **5**: e2021060 [DOI: 10.29392/001c.24940]
- 50 **Sarin SK**, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-El Salam S, Hwang J, Qi X, Cua IH, Suh JJ, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M; APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study

- (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). *Hepatol Int* 2020; **14**: 690-700 [PMID: 32623632 DOI: 10.1007/s12072-020-10072-8]
- 51 **Dahlin P**, Nagras ZG, Attauabi M, Burisch J, Bendtsen F, Kimer N. Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study. *GastroHep* 2022; **2022** [DOI: 10.1155/2022/8081932]
 - 52 **Simon TG**, Hagström H, Sharma R, Söderling J, Roelstraete B, Larsson E, Ludvigsson JF. Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study. *BMC Gastroenterol* 2021; **21**: 439 [PMID: 34814851 DOI: 10.1186/s12876-021-02017-8]
 - 53 **Li C**, Chen Q, Wang J, Lin H, Lin Y, Lin J, Peng F, Chen J, Yang Z. Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China. *Aging (Albany NY)* 2020; **12**: 15938-15945 [PMID: 32855361 DOI: 10.18632/aging.103632]
 - 54 **Váncsa S**, Hegyi PJ, Zádori N, Szakó L, Vörhendi N, Ocskay K, Földi M, Dembrovszky F, Dömötör ZR, Jánosi K, Rakonczay Z Jr, Hartmann P, Horváth T, Erőss B, Kiss S, Szakács Z, Németh D, Hegyi P, Pár G. Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review. *Front Med (Lausanne)* 2020; **7**: 572115 [PMID: 33282888 DOI: 10.3389/fmed.2020.572115]
 - 55 **Nagarajan R**, Krishnamoorthy Y, Rajaa S, Hariharan VS. COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis. *Prev Chronic Dis* 2022; **19**: E53 [PMID: 36007255 DOI: 10.5888/pcd19.210228]
 - 56 **Hartl L**, Haslinger K, Angerer M, Semmler G, Schneeweiss-Gleixner M, Jachs M, Simbrunner B, Bauer DJM, Eigenbauer E, Strassl R, Breuer M, Kimberger O, Laxar D, Lampichler K, Halilbasic E, Stättermayer AF, Ba-Ssalamah A, Mandorfer M, Scheiner B, Reiberger T, Trauner M. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. *Hepatology* 2022; **76**: 1563-1575 [PMID: 35596929 DOI: 10.1002/hep.32582]
 - 57 **Mani I**, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. *Ann Gastroenterol* 2021; **34**: 625-633 [PMID: 34475732 DOI: 10.20524/aog.2021.0628]
 - 58 **Zhang B**, Huang W, Zhang S. Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients With Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol* 2020; **18**: 2633-2637 [PMID: 32553905 DOI: 10.1016/j.cgh.2020.06.011]
 - 59 **Liu R**, Zhao L, Cheng X, Han H, Li C, Li D, Liu A, Gao G, Zhou F, Liu F, Jiang Y, Zhu C, Xia Y. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. *Liver Int* 2021; **41**: 720-730 [PMID: 33351265 DOI: 10.1111/liv.14774]
 - 60 **Kang SH**, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. *PLoS One* 2021; **16**: e0258229 [PMID: 34610052 DOI: 10.1371/journal.pone.0258229]
 - 61 **Yu Y**, Li X, Wan T. Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis. *Dig Dis Sci* 2022; **1-17** [PMID: 36085229 DOI: 10.1007/s10620-022-07687-2]
 - 62 **Alqahtani SA**, Buti M. COVID-19 and hepatitis B infection. *Antivir Ther* 2020; **25**: 389-397 [PMID: 33616549 DOI: 10.3851/IMP3382]
 - 63 **Ronderos D**, Omar AMS, Abbas H, Makker J, Baiomi A, Sun H, Mantri N, Choi Y, Fortuzzi K, Shin D, Patel H, Chilimuri S. Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. *World J Clin Cases* 2021; **9**: 8749-8762 [PMID: 34734053 DOI: 10.12998/wjcc.v9.i29.8749]
 - 64 **Choe JW**, Jung YK, Yim HJ, Seo GH. Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database. *J Korean Med Sci* 2022; **37**: e29 [PMID: 35075828 DOI: 10.3346/jkms.2022.37.e29]
 - 65 **Xu Y**, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. *Lipids Health Dis* 2021; **20**: 126 [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z]
 - 66 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044]
 - 67 **Hegyi PJ**, Váncsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, Erőss B, Szakács Z, Hegyi P, Pár G. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis. *Front Med (Lausanne)* 2021; **8**: 626425 [PMID: 33777974 DOI: 10.3389/fmed.2021.626425]
 - 68 **Vrsaljko N**, Samadan L, Viskovic K, Mehmedović A, Budimir J, Vince A, Papic N. Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study. *Open Forum Infect Dis* 2022; **9**: ofac073 [PMID: 35287335 DOI: 10.1093/ofid/ofac073]
 - 69 **Moon AM**, Curtis B, Mandrekar P, Singal AK, Verna EC, Fix OK. Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing Investigation. *Hepatol Commun* 2021; **5**: 1616-1621 [PMID: 34510833 DOI: 10.1002/hep4.1747]
 - 70 **Marjot T**, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. *J Hepatol* 2021; **74**: 567-577 [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024]
 - 71 **Singh S**, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology* 2020; **159**: 768-771.e3 [PMID: 32376408 DOI: 10.1053/j.gastro.2020.04.064]
 - 72 **Nawghare P**, Jain S, Chandnani S, Bansal S, Patel S, Debnath P, Rane S, Deshmukh R, Rath P, Contractor Q. Predictors of Severity and Mortality in Chronic Liver Disease Patients With COVID-19 During the Second Wave of the Pandemic in

- India. *Cureus* 2022; **14**: e20891 [PMID: [35145796](#) DOI: [10.7759/cureus.20891](#)]
- 73 **Iavarone M**, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020; **73**: 1063-1071 [PMID: [32526252](#) DOI: [10.1016/j.jhep.2020.06.001](#)]
- 74 **Moon AM**, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genesca J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. *J Hepatol* 2020; **73**: 705-708 [PMID: [32446714](#) DOI: [10.1016/j.jhep.2020.05.013](#)]
- 75 **Jeon D**, Son M, Choi J. Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea. *Korean J Intern Med* 2021; **36**: 1092-1101 [PMID: [34399573](#) DOI: [10.3904/kjim.2020.486](#)]
- 76 **Satapathy SK**, Roth NC, Kvasnovsky C, Hirsch JS, Trindade AJ, Molmenti E, Barish M, Hirschwerk D, Da BL, Bernstein D; Northwell Health COVID-19 Research Consortium. Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study. *Hepatol Int* 2021; **15**: 766-779 [PMID: [33826042](#) DOI: [10.1007/s12072-021-10181-y](#)]
- 77 **Chagas AL**, Fonseca LGD, Coelho FF, Saud LRDC, Abdala E, Andraus W, Fiore L, Moreira AM, Menezes MR, Carnevale FC, Tani CM, Alencar RSSM, D'Albuquerque LAC, Herman P, Carrilho FJ. Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement. *Clinics (Sao Paulo)* 2020; **75**: e2192 [PMID: [33146360](#) DOI: [10.6061/clinics/2020/e2192](#)]
- 78 **Muñoz-Martínez S**, Sapena V, Forner A, Bruix J, Sanduzzi-Zamparelli M, Ríos J, Bouattour M, El-Kassas M, Leal CRG, Mocan T, Nault JC, Alves RCP, Reeves HL, da Fonseca L, García-Juárez I, Pinato DJ, Varela M, Alqahtani SA, Alvares-da-Silva MR, Bandi JC, Rimassa L, Lozano M, González Santiago JM, Tacke F, Sala M, Anders M, Lachenmayer A, Piñero F, França A, Guarino M, Elvevi A, Cabibbo G, Peck-Radosavljevic M, Rojas Á, Vergara M, Braconi C, Pascual S, Perelló C, Mello V, Rodríguez-Lope C, Acevedo J, Villani R, Hollande C, Vilgrain V, Tawheed A, Ferguson Theodoro C, Sparchez Z, Blaise L, Viera-Alves DE, Watson R, Carrilho FJ, Moctezuma-Velázquez C, D'Alessio A, Iavarone M, Reig M. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. *Liver Int* 2022; **42**: 1891-1901 [PMID: [35608939](#) DOI: [10.1111/liv.15320](#)]
- 79 **Pazgan-Simon M**, Kucharska M, Górka-Dynysiewicz J, Simon K. Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma. *Pharmacol Rep* 2022; **74**: 1306-1314 [PMID: [36394820](#) DOI: [10.1007/s43440-022-00434-4](#)]
- 80 **Guarino M**, Cossiga V, Capasso M, Mazzarelli C, Pelizzaro F, Sacco R, Russo FP, Vitale A, Trevisani F, Cabibbo G; The Associazione Italiana Per Lo Studio Del Fegato AISF HCC Special Interest Group. Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma. *J Clin Med* 2022; **11** [PMID: [35956091](#) DOI: [10.3390/jcm11154475](#)]
- 81 **Li P**, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. *Biomed Pharmacother* 2022; **154**: 113568 [PMID: [36029543](#) DOI: [10.1016/j.biopha.2022.113568](#)]
- 82 **Floreani A**, De Martin S. COVID-19 and Autoimmune Liver Diseases. *J Clin Med* 2022; **11** [PMID: [35628807](#) DOI: [10.3390/jcm11102681](#)]
- 83 **Marjot T**, Buescher G, Sebode M, Barnes E, Barritt AS 4th, Armstrong MJ, Baldelli L, Kennedy J, Mercer C, Ozga AK, Casar C, Schramm C; contributing Members and Collaborators of ERN RARE-LIVER/COVID-Hep/SECURE-Cirrhosis, Moon AM, Webb GJ, Lohse AW. SARS-CoV-2 infection in patients with autoimmune hepatitis. *J Hepatol* 2021; **74**: 1335-1343 [PMID: [33508378](#) DOI: [10.1016/j.jhep.2021.01.021](#)]
- 84 **Efe C**, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kılıcı M, Akylidiz M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. *Hepatology* 2021; **73**: 2099-2109 [PMID: [33713486](#) DOI: [10.1002/hep.31797](#)]
- 85 **Zecher BF**, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse AW, Sebode M. Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. *United European Gastroenterol J* 2021; **9**: 797-808 [PMID: [34105883](#) DOI: [10.1002/ueg2.12100](#)]
- 86 **Ampuero J**, Lucena A, Hernández-Guerra M, Moreno-Moraleda I, Arenas J, Conde I, Muñoz L, Canillas L, Fernandez E, Quiñones R, Simon MA, Gómez-Domínguez E, Gutierrez ML, Fernandez-Rodríguez C, Domper-Arnal MJ, Jorquera F, Garcia-Buey ML, Garcia-Retortillo M, Morillas R, Berenguer M, Casado M, Morales-Arreaz D, Sousa JM, Molina E. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. *Gut* 2021 [PMID: [34876479](#) DOI: [10.1136/gutjnl-2021-325700](#)]
- 87 **Mallet V**, Beeker N, Bouam S, Sogni P, Pol S; Demosthenes research group. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. *J Hepatol* 2021; **75**: 848-855 [PMID: [33992699](#) DOI: [10.1016/j.jhep.2021.04.052](#)]
- 88 **Lippi G**, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis. *Eur J Gastroenterol Hepatol* 2021; **33**: 114-115 [PMID: [32282549](#) DOI: [10.1097/MEG.0000000000001742](#)]
- 89 **Martínez MA**, Franco S. Impact of COVID-19 in Liver Disease Progression. *Hepatol Commun* 2021; **5**: 1138-1150 [PMID: [34533001](#) DOI: [10.1002/hep4.1745](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

